<?xml version='1.0' encoding='utf-8'?>
<document id="28249706"><sentence text="Preincubation-dependent and long-lasting inhibition of organic anion transporting polypeptide (OATP) and its impact on drug-drug interactions." /><sentence text="Preincubation with cyclosporin A (CsA), a potent inhibitor of organic anion transporting polypeptide 1B1 (OATP1B1) and OATP1B3, enhanced its inhibitory effects on these transporters in vitro"><entity charOffset="19-32" id="DDI-PubMed.28249706.s2.e0" text="cyclosporin A" /><entity charOffset="34-37" id="DDI-PubMed.28249706.s2.e1" text="CsA" /><pair ddi="false" e1="DDI-PubMed.28249706.s2.e0" e2="DDI-PubMed.28249706.s2.e0" /><pair ddi="false" e1="DDI-PubMed.28249706.s2.e0" e2="DDI-PubMed.28249706.s2.e1" /></sentence><sentence text=" A similar effect was observed upon preincubation with some other inhibitors" /><sentence text=" Removing these from the incubation media did not readily reverse the inhibition on OATP1B1 and OATP1B3" /><sentence text=" This preincubation-dependent long-lasting inhibition appeared to be related to CsA concentration in the cells in addition to that in the incubation media"><entity charOffset="80-82" id="DDI-PubMed.28249706.s5.e0" text="CsA" /></sentence><sentence text=" Thus, we hypothesized that CsA inhibits OATP1B1 and OATP1B3 from inside (trans-inhibition) as well as outside (cis-inhibition) the cells and constructed the cis- and trans-inhibition model"><entity charOffset="28-30" id="DDI-PubMed.28249706.s6.e0" text="CsA" /></sentence><sentence text=" The enhanced inhibitory effect of CsA on OATP1B1 observed after preincubation was quantitatively described using Ki,out and Ki,in as inhibition constants for cis- and trans-inhibitions, respectively"><entity charOffset="35-37" id="DDI-PubMed.28249706.s7.e0" text="CsA" /></sentence><sentence text=" In addition, a long-lasting inhibition was also described by this model" /><sentence text=" Additional factors taken into consideration when simulating in vivo pharmacokinetic alterations by CsA are potential inhibition by AM1, a major metabolite of CsA, which has been reported to inhibit OATP1B1 and OATP1B3"><entity charOffset="100-102" id="DDI-PubMed.28249706.s9.e0" text="CsA" /><entity charOffset="159-161" id="DDI-PubMed.28249706.s9.e1" text="CsA" /><pair ddi="false" e1="DDI-PubMed.28249706.s9.e0" e2="DDI-PubMed.28249706.s9.e0" /><pair ddi="false" e1="DDI-PubMed.28249706.s9.e0" e2="DDI-PubMed.28249706.s9.e1" /></sentence><sentence text=" Based on the physiologically based pharmacokinetic model incorporating trans- and cis-inhibition of OATP1B1 by CsA, the simulation showed that OATP1B1-mediated drug-drug interaction with CsA was suggested to be time-dependent also in vivo although further clinical studies are required for confirmation"><entity charOffset="112-114" id="DDI-PubMed.28249706.s10.e0" text="CsA" /><entity charOffset="188-190" id="DDI-PubMed.28249706.s10.e1" text="CsA" /><pair ddi="false" e1="DDI-PubMed.28249706.s10.e0" e2="DDI-PubMed.28249706.s10.e0" /><pair ddi="false" e1="DDI-PubMed.28249706.s10.e0" e2="DDI-PubMed.28249706.s10.e1" /></sentence><sentence text="" /></document>